ARK Genomic Revolution ETF

ARKG

Market cap $1.3B

ARK Genomic Revolution ETF (ARKG) maintains a "Buy" rating, driven by strong technicals and momentum despite a premium valuation. ARKG has outperformed XLV and SPY over the past year, returning 23% since July and beating the S&P 500 by 12 percentage points. The ETF's concentrated, small-cap, high-risk portfolio is supported by rising AUM, robust liquidity, and a bullish technical breakout.

Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes for 2026 that investors should watch. This year's list comes after the firm reported a strong 2025, with its ETFs outperforming the S&P 500.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

I maintain a hold rating on ARK Genomic Revolution ETF due to unprofitable top holdings, high operating costs, and limited approved treatments despite revenue growth. ARKG's high expense ratio and lack of dividend yield make it less attractive compared to peer genomic ETFs with better performance and lower fees. Top holdings like Tempus AI, CRISPR Therapeutics, and Twist Bioscience are either overvalued or struggle with profitability, limiting ARKG's upside.

Ark Invest CEO Cathie Wood is known for her stock picks over the last decade, handpicking many of the growth stocks that find their way into the company's ETFs.

I reiterate a soft buy rating on ARKG, despite recent sector weakness and mixed technicals, due to its rebound and improving valuation. ARKG stands out for its concentrated portfolio, high risk/reward profile, and focus on the genomics revolution, though it lacks a dividend yield. The ETF has rebounded 42% off April lows, outperforming the S&P 500, but faces seasonal headwinds and resistance near $28-$31.

It's probably time to give Cathie Wood the benefit of the doubt as the tides turn back in disruptive innovation's favor.

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?